The studies of potentiation of 5-fluorouracil (5-FU), a traditional drug used in the treatment of 20 several cancers, including colorectal (CRC), were carried out with zeolites Faujasite in the 21 sodium form, with different particle sizes (NaY, 700 nm and nanoNaY, 150 nm) and Linde 22 type L in the potassium form (LTL) with a particle size of 80 nm. 
Introduction 40
Colorectal carcinoma (CRC) is one of the most common types of cancer in industrialized 41 countries, slightly more prevalent in men than women [1] . Generally, the treatment of CRC 42 includes surgery, radiotherapy and/or chemotherapy. The treatment design depends, however, 43 largely on the cancer stage. Although for patients with an early-stage disease, surgery gives a 44 relatively good prognosis; patients in a more advanced disease stage often require adjuvant 45 chemotherapy to reduce cancer and the high risk of recurrence [2] [3] [4] . (v/v) penicillin-streptomycin solution (P/S) (Invitrogen, USA) and incubated at 37 °C in a 5% 135 CO 2 humidified atmosphere. Cells were subcultured approximately every three days and 136 maintained in a log-phase growth. 137
Cell viability was assessed using the In Vitro Toxicology Assay Kit, Sulforhodamine B based 138 (Sigma-Aldrich, St. Louis, MO, USA). HCT-15 (7500 cells/100µL/well) and RKO (6000 139 cells/100µL/well) cells were seeded in 96-well plates and incubated at 37 °C in a 5% CO 2 140 humidified atmosphere for 24 h. In order to assess the effects of the starting zeolites, 5-FU 141
and DDS used and cells were incubated with increasing concentrations of the systems in 142 culture medium. Controls were performed with culture medium alone. After an incubation 143 period of 48 h, the spent media were removed and the plate wells were washed with 1x 144
Phosphate-buffered solution, pH 7.4 (PBS). After a fixation step with cold 10% 145 trichloroacetic acid (TCA), cells were stained with 0.4% Sulforhodamine B and the 146 incorporated dye was solubilized with Sulforhodamine B solubilization solution (10 mM 147 Tris). Absorbance was monitored with a microplate reader at 570 nm with a background 148 absorbance of 655 nm. Cell viability was determined as percentage of viability: (OD 149 experiment/OD control) x 100 (%). Results are presented as mean ± standard deviation (SD) 150 of three independent experiments, each in triplicate. One-way ANOVA, followed by Dunnett 151 post test (Fig. 6 and 7) were used to perform cell viability assay statistical analysis. The 152 previous tests and 50% growth inhibition (IC 50 ) were determined using the Graphpad Prism 153 5 ® software. Values were considered statistically significant in all experiments when p<0.05. 154 2.5. Fluorescence microscopy assays 155 7 HCT-15 (10000 cells/500µL/well) and RKO (50000 cells/500µL/well) cell lines were seeded 156 on coverslips in 24-well plates and incubated at 37 ºC in a 5% CO 2 atmosphere for 24 h. 157 Spent media were removed, cells were washed with PBS 1x and then incubated with 0.025 158 mg/mL of RhodamineB@NaY during 48 h. Cells were washed twice with PBS-Tween 0.05% 159 (PBST 0.05%), fixed with cold methanol during 10 min, washed twice with PBST 0.05% and 160 permeabilized with PBST 0.01% for 10 min. 161
Next, and after two washes with PBST 0.05%, cells were blocked with FBS 10% in PBST 162 0.05% during 30 min and then incubated with anti-β-tubulin antibody (ab6046, Abcam®) 163 diluted in FBS 5% in PBST 0.05% (1:700) during 1 h at room temperature. In the next step, 164 cells were washed three times with PBST 0.05% (10 min each) and incubated with the 165 secondary antibody anti-rabbit Alexa Fluor 488 (A11008, Invitrogen) diluted in FBS 5% in 166 PBST 0.05% (1:1000) during 1 h at room temperature. Finally, after three washes with PBST 167 0.05% (10 min each) and one wash with PBS (5 min), cells were mounted in Vectashield 168 mounting media with 4',6'-diamidino-2'-phenylindole (DAPI) (Vector Laboratories). Images 169 were acquired in an Olympus IX81 fluorescence microscope (Tokyo, Japan), using Cell P 170 software. 171
Characterization methods 172
The textural characterization of the zeolites was based on the N 2 adsorption isotherms, 173 determined at -196 ºC with a Quantachrome NOVA 4200e apparatus. NaY presents a larger micropore volume than the other zeolites, suggesting that this zeolite 236 has a higher capacity for 5-FU loading, since it adsorbs preferentially on the micropores (see 237 supplementary data). 238
The release profiles of 5-FU from zeolites, NaY, nanoNaY and LTL are shown in Fig. 1 FU release profiles seems to be not dependent of the framework structure of the zeolites, 3D 251 (Y zeolite) or 1D (LTL zeolite). The diffusion from within the zeolite pores and channels 252 appears to be no different from the internal surface or even from the aggregate of particles. 253
In order to establish the best release profile, the DDS release kinetic profiles were modeled by 254 fitting the mathematical kinetic models usually used to describe in vitro drug dissolution and 255 release from pharmaceutical dosage forms [40] , including the zero-order (Q t = Q 0 +K 0 t), first-256 order (lnQ t = lnQ 0 +K t t), Higuchi (Q t = K H √t), Hixson-Crowell (Q 0 1/3 -Q t 1/3 = K s t), Korsmeyer-257 Peppas (Q t /Q ∞ = K k t n ) and Weibull (log[-ln(1-(Q t /Q ∞ ))] = blogt-loga) models [40] . The release 258 models with major application and best describing drug release are the zero-order, Higuchi, 259
Korsmeyer-Peppas and Weibull models [40, 41] . The fitted data for the selected release kinetic 260 models are listed in 
266
The in vitro drug release from zeolites was best described by the Weibull model, as the plots 267 showed the highest linearity. The Weibull model is more useful for comparing the release 268 profiles of matrix-type drug delivery [41] . This model describes the dissolution curve in terms 269 of applicable parameters and is able to empirically describe, but not mechanistically 270 characterize, the dissolution behavior of the dosage form. The advantage of the Weibull 271 model lies on its ability to fit almost any kind of dissolution curve and it is, therefore, often 272 used to describe experimental data, especially when the mechanism of release underlying the 273 dissolution behavior is unknown [42] . In this model, the shape parameter, b, characterizes the 274 13 curve as exponential (b=1, case 1), sigmoid, S-shaped, with upward curvature followed by a 275 turning point (b>1, case 2), or parabolic, with a higher initial slope and after that consistent 276 with the exponential (b<1, case 3) [40] [41] [42] . The b parameter obtained after fitting the release 277 data was 0.37, 0.30 and 0.51 for 5-FU@NaY, 5-FU@nanoNaY and 5-FU@LTL, respectively. 278
These values are consistent with case 3 exhibiting higher initial slope followed by an 279 exponential curvature, as it is evident from the release profiles for all DDS in Fig. 1.  280 The rapid release of 5-FU from zeolites may be rationalized in terms of the size of the drug 281 and its interactions with the zeolite frameworks. 5-FU is a small molecule with molecular 282 with no measurable shifts indicating that the drug is present and not interacting strongly with 310 the zeolitic frameworks. 311 312
3.2-Drug bioactivity studies 313
The cytotoxicity studies were carried out in two different cancer cell lines, HCT-15 and RKO. 314
These lines are well characterized human colorectal carcinoma cells, with different 315 phenotypes and genetic backgrounds. These cells were chosen as predictive models to test the 316 potentiation of the chemotherapeutic agent 5-FU into the zeolites NaY, nanoNaY and LTL. 317
Viability of HCT-15 and RKO cells was evaluated by the sulforhodamine B (SRB) assay, 318 which measures the drug-induced cytotoxicity and cell proliferation, used for large-scale 319 drug-screening applications [45] . 320
The drug bioactivity studies were performed by preparing five working DDS concentrations, 321 by diluting a stock suspension (1.0 mg/mL) in culture medium. For better homogenization, all 322 suspensions were submitted to ultrasonic dispersion for 2 min prior to use. This procedure 323 was optimized in our previous work [31] . 324
The cytotoxicity of the starting zeolites, NaY, nanoNaY and LTL, was investigated in HCT-325 15 and RKO cell lines to assess their suitability as DDS. In both cell lines, all zeolites gave 326 LTL, led to a reduction in cell viability from 64 to 34%, 66 to 43% and 67 to 46% comparing 348 with cells treated with the starting zeolite. In RKO cells (Fig. 3) , incubation of the 5-349
FU@zeolite systems resulted also in a significant decrease in cell viability for the three 350 (Table  356 3). 357 Table 3 In order to assess the interaction between the zeolites and the CRC cells, fluorescence 374 microscopy assays were performed. Fig. 4 shows the results where HCT-15 and RKO cells 375 were treated with the NaY zeolite loaded with the fluorescent compound Rhodamine B. 376
Comparing the control images with those with RhodamineB@NaY, it is possible to observe 377 that the zeolite is able to enter the cell cytoplasm. Although this approach was only applied to 378 NaY zeolite, it is expected that both nanoNaY and LTL zeolites are also able to enter the cells 379 due to their smaller dimensions, where internalization would be even easier. Extrapolating 380 these results for the DDS, it is likely that the drug release is achieved inside the cells if the 381 DDS is put in contact with them. 19 390
By encapsulating 5-FU into zeolites, we increased significantly the efficiency of this drug. 391
We believe that similarly to other systems [16, [46] [47] [48] , the zeolite DDS allow the release of 5-392 FU, increasing the bioavailability of the drug, and thus explaining the increase in potency. 393
Moreover, the entry of 5-FU into the cells could also contribute to the high increase in 394 potency observed. Thus, this potency rise could be the combined result of both the increase in 395 5-FU bioavailability and the facilitation of 5-FU entry into the cell by the DDS. 396 397
4-Conclusions 398
5-FU was successfully loaded into the zeolite structures with different particle sizes, NaY 399 (700 nm) and two nanosized zeolites, nanoNaY (150 nm) and nanoLTL (80 nm) and the 400 loading of 5-FU was found to be highest in NaY followed by nanoNaY and LTL. FTIR and 401 solid-state NMR ( 13 C and 27 Al) provided no evidence for significant framework-drug 402 interactions. The release of the drug from the zeolite structures in buffer solution at pH = 7.4 403 and 37 °C followed the Weibull model. The effect of the zeolites and DDS on HCT-15 and 404 RKO human colon carcinoma cell lines viability was evaluated. DDS based on zeolites were 405 able to increase the efficiency of 5-FU, a widely used anticancer drug. We believe these 406 systems should be further explored in other cancer models, e.g. in vivo models, to confirm the 407 efficiency of the systems. 
